Quick Answer
Corvus Pharmaceuticals, Inc. reported Research And Development Expense of $33.72 million for the year ending 2025.
- Corvus Pharmaceuticals, Inc. showed an increase of +73.9% in Research And Development Expense from 2024 to 2025.
- This data is from Corvus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Corvus Pharmaceuticals, Inc.'s Research And Development Expense has grown by 88,634.2%.
- Historical annual values: Fiscal year 2025: $33.72 million | Fiscal year 2024: $19.39 million | Fiscal year 2023: $16.53 million | Fiscal year 2022: $24.47 million | Fiscal year 2021: $29.12 million | Fiscal year 2020: $31.83 million | Fiscal year 2019: $37.98 million | Fiscal year 2018: $38.59 million | Fiscal year 2017: $46.31 million | Fiscal year 2016: $29.36 million | Fiscal year 2015: $11.35 million | Fiscal year 2014: $38.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: